NASDAQ · KRRO
Korro Bio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for KRRO: Nov 11, 2026
Korro Bio, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.14. The reported EPS for the same quarter last year was $-1.92.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.14 | $-0.93 | $-1.41 | 5 |
| Dec 2026 | $-1.30 | $-0.74 | $-2.41 | 5 |
| Mar 2027 | $-1.06 | $-0.78 | $-1.25 | 3 |
| Jun 2027 | $-1.09 | $-0.89 | $-1.22 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel · BNK Invest- Zacks · Oct 23, 5:47 AM EDTKorro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?Korro Bio, Inc. (KRRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- RTTNews · Oct 22, 3:29 PM EDTBiotech Stocks Rally: BHVN Jumps 31%, KRRO Climbs 25%, ATNM And VCRE Gain(RTTNews) – Shares of several biotech companies moved higher following corporate and clinical developments. Biohaven gained after the FDA accepted its resubmitted drug application for spinocerebellar ataxia, Korro Bio reported positive preclinical results for its AATD candidate,
- Fintel · Oct 22, 10:54 AM EDTKorro Bio Announces Preclinical Results for KRRO-111Korro Bio, Inc. announced preclinical results for KRRO-111, its development candidate for the potential treatment of Alpha-1 Antitrypsin Deficiency. KRRO-111 is a proprietary GalNAc-conjugated RNA-editing oligonucleotide administered subcutaneously and selectively taken up by liv
- RTTNews · Oct 7, 1:34 AM EDTKorro Bio Doses First Cohort In Phase 1/2 Study Of KRRO-121 For Hyperammonemia(RTTNews) – Korro Bio Inc. (KRRO), a clinical-stage biopharmaceutical company, on Tuesday reported the dosing of the first cohort in the Phase 1/2 study of KRRO-121 for treating hyperammonemia in patients of urea cycle disorders and hepatic encephalopathy. Urea cycle disorder (
- Zacks · Aug 10, 12:00 PM EDTAll You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to BuyKorro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · Jul 27, 7:45 AM EDTStrength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength?Ono Pharmaceutical Co. (OPHLF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- Zacks · Jul 8, 12:00 PM EDTKorro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?Korro Bio, Inc. (KRRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks · Jun 19, 8:06 AM EDTKorro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- RTTNews · May 20, 11:09 AM EDTKorro Bio To Advance KRRO-111 As Potential Treatment For AATD(RTTNews) – Korro Bio Inc. (KRRO), a biopharmaceutical company, has selected KRRO-111 as a development candidate for clinical advancement in the potential treatment of alpha-1 antitrypsin deficiency.
- Fintel · May 18, 8:04 PM EDTCitigroup Initiates Coverage of Korro Bio (KRRO) with Buy RecommendationFintel reports that on May 18, 2026, Citigroup initiated coverage of Korro Bio (NasdaqCM:KRRO) with a Buy recommendation. Analyst Price Forecast Suggests 101.45% Upside
- BNK Invest · May 18, 3:22 PM EDTNotable Monday Option Activity: ADBE, KRRO, CALMAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Adobe Inc (Symbol: ADBE), where a total of 37,698 contracts have traded so far, representing approximately 3.8 million underlying shares. That amounts to about 74.9% of
- Zacks · Apr 28, 12:00 PM EDTWhat Makes Korro Bio, Inc. (KRRO) a New Buy StockKorro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Korro Bio, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.